At page 20, line 28, after "f-Met-Leu-Tyr-Tyr" insert--(SEQ ID NO:5)--.

At page 21, line 2, after "f-Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

At page 21, line 4, after "Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

NG. At page 19, line 6, after "f-Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

At page 21, line 10, after "f-Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

In the Claims:

REMARKS

In the Office Action dated September 24, 1999, claims 1-20 are pending, claims 4-20 are withdrawn from consideration, and claims 1-3 are rejected.

A "Sequence Listing" as required by 37 C.F.R. § 1.812(c) is submitted herewith including (i) an initial computer readable from (CRF) copy of the "Sequence Listing"; (ii) an initial paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification; and (iii) a statement that the content of the paper and CRF are the same and include no new matter.

Claims 1-2 are rejected under 35 U.S.C. 103(a), as being unpatentable over Gleisner (*Inflammation* 1981)in view of Oxford dictionary of Biochemistry and Molecular Biology (1981) and Casale and Dimitrascu, and further in view of Kermode, Ferry and Anderson.

Gleisner states that f-Met-Leu-Phe was the most potent inhibitor of mast cell degranulation tested using the rat skin model. He also states that Met-Phe was ineffective. (Page 14, Results)